Untimely Tissue Standards Can Stall Product Development – CBER Rep
This article was originally published in The Gray Sheet
Executive Summary
Premature standards development for tissue-engineered medical products (TEMPs) could delay their entry into the market, according to Joyce Frey-Vasconcells, acting deputy director of CBER's Office of Cellular, Tissue & Gene Therapies